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Abstract 
Six tyrosine residues (Y28, Y 143, Y292, Y293, Y308, Y432’) which are conserved in all mammalian glucose transporters were substituted for 
phenylalanine by site-directed mutagenesis, and mutant glucose transporters were transiently expressed in COS-7 cells. Glucose transport activity 
as assessed by reconstitution of the solubilized transporters into lecithin liposomes was reduced by 70% in the mutant Yl43F and appeared to be 
abolished in Y293F, but was not affected by substitution of Y28, Y292, Y308 and Y432. In contrast, covalent binding of the photolabel “‘IAPS- 
forskolin was normal in all mutants. Stable expression of the mutants Yl43F, Y293F, and Y292F in LTK cells yielded identical results. These data 
indicate that only two of the 6 conserved helical tyrosine residues, located in helices 4 and 7, are essential for full activity, but not for IAPS-forskolin 
binding of the GLUT4. 
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1. Introduction 
Glucose transport into mammalian cells is catalyzed 
by a family of homologous proteins (GLUTl-GLUT4) 
exhibiting a striking tissue specificity [l]. All glucose 
transporter isoforms consist of 12 hydrophobic helices 
representing membrane spanning domains, intracellular 
C- and N-termini, and large extracellular and intracellu- 
lar domains [2]. These proteins differ in some functional 
characteristics, e.g. &-values [3] and binding affinities 
of the inhibitory ligands cytochalasin B and forskolin [4]. 
The structural basis of the function of glucose trans- 
porters, and of their functional differences is not fully 
known, although a hypothetical model involving a con- 
formational change within pore-forming helices is gener- 
ally accepted [5]. 
Several amino acid residues in the GLUT1 have previ- 
*Corresponding author. Fax: (49) (241) 8888433. 
Abbreviations: ATB-BMPA, 2-N4-(1-azi-2,2,2-trifluoroethyl)benzoyl- 
1,3-bis(D-mannosyloxy)-2-propylamine; [‘2SI]IAPS-forskolin, 3-[‘*‘I]- 
Iodo-4-azidophenetyl-amido-7-O-succinyldeacetyl-forskolin; GLUTl, 
erythrocyte/brain-type glucose transporter; GLUT4, adipocyte/muscle- 
type glucose transporter; PMSF, phenylmethylsulfonylfluoride; SDS- 
PAGE, sodium dodecylsulfate polyacrylamide gel electrophoresis. 
‘In order to facilitate comparisons, the tyrosines in the GLUT4 are 
numbered corresponding with those in the GLUTl. The positions ac- 
cording to the numbering of the GLUT4 are (in parentheses): Y28 (40), 
Y143 (159), Y292 (308), Y293 (309), Y308 (324), Y432 (448). 
ously been exchanged by mutagenesis in order to define 
residues that are essential for transporter function. So 
far, these data have generated a complex picture of heter- 
ogenous requirements for transporter function and bind- 
ing of ligands such as the bis-mannose derivative ATB- 
BMPA, cytochalasin B, and forskolin. Two tryptophane 
residues have been identified as potential contact sites of 
glucose and/or inhibitory ligands, e.g. cytochalasin B 
and forskolin: exchange of W388 in helix 10 markedly 
affected both glucose transport activity and affinity for 
inhibitory ligands, whereas the exchange of W412 in 
helix 11 exclusively reduced transporter activity [6,7]. 
Substitution of 4282 in helix 7 led to the suggestion that 
this domain is involved in the exofacial binding of sugars 
[8]. Furthermore, exchange of C421 decreased the inhib- 
itory potency of cytochalasin B but failed to affect the 
transport activity of the GLUT1 [9]. 
All mammalian glucose transporters harbor 6 con- 
served tyrosines in their membrane spanning helices. 
Based on the hypothesis that the hydroxyl groups of the 
helical tyrosines might participate in the recognition of 
the hexose or in the interaction of the pore-forming he- 
lices, we have exchanged these tyrosine residues for 
phenylalanine. We have chosen the GLUT4 for this pur- 
pose, since this isoform exhibits an extraordinarily high 
affinity for the ligand forskolin [4]. Furthermore, trans- 
fected GLUT4 can easily be detected and quantitated in 
the presence of the constitutive GLUTl. The mutants 
were expressed in COS-7 cells, and their activity and 
photolabeling by IAPS-forskolin was assessed in an in 
vitro system of isolated membranes. 
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2. Materials and methods 
2.1. Construction of mutant DNA and expression vectors 
Mutants were generated by oligonuclebtide-directed mutagenesis as 
described 1101. Single stranded DNA of rat GLUT4 1111 subcloned into 
pBluescript was u&d as the template. Mutated con&cts were identi- 
fied by sequencing and subcloned as XbaI-KpnI fragments from 
pBluescript into the mammalian expression vector pCMV which har- 
bors a SV40 origin, a cytomegalovirus promoter, and a polyadenylation 
site [12]. 
2.2. Transfection of CO97 cells 
Transfection of COS-7 cells with glucose transporter cDNA was 
performed by a modification of the previously described procedure [ 121. 
COS-7 cells were obtained from American Type Culture Collection 
(Rockville, MD) and were grown in Dulbecco’s modified Eagle’s me- 
dium (pH 7.4) containing 10% fetal calf serum, 20 mM HEPES, and 
2 mM glutamine. The cells were harvested by trypsination 24 h before 
the transfection and were seeded onto 153 cm’ culture dishes at a final 
density of 6.25 x 10’ cells/dish. Four hours before the transfection. 25 
ml fresh culture medium was added to the monolayer. DNA (25 ‘& 
plate) was co-precipitated with 125 mM CaCl, in HBS-buffer (140 mM 
NaCl, 0.75 mM Na,HPO, .2H,O, 25 mM HEPES, pH 7.1) for 15 min 
in a final volume of 2.5 ml. The calcium phosphate-DNA suspension 
was added to the monolayers, and cells were incubated for 16 h at 37°C. 
Thereafter, the medium was exchanged for 7.5 ml 15% glycerol in 
HBS-buffer, and the cells were incubated for 3 min. The buffer was 
removed by aspiration, and monolayers were washed twice with pre- 
warmed PBS (138 mM NaCl, 2.6 mM KCl, 10 mM Na,HPO,, 1.8 mM 
KH,PO,, pH 7.4). The cells were then incubated with fresh culture 
medium in an atmosphere of 5% CO2 at 37°C for 48 h. 
2.3. Transfection of LTK-cells 
LTK cells were cultured in Eagle’s minimum essential medium, pH 
7.4, supplemented with 10% fetal calf serum, 2 mM glutamine, and 20 
mM HEPES at 37°C in an atmosphere of 5% CO,. Twenty-four hours 
before transfection, the cells were seeded in 83 cm* culture flasks at a 
density of 10’ cells/flask and cultured overnight. After a 4 h incubation 
with fresh medium, 10 pg of plasmid DNA(pCMV, pCMV-GLUT4, 
pCMV-GLUT4-Yl43F, pCMV-GLUT4-Y292F, pCMV-GLUT4- 
Y293F) and 1 pg of the plasmid harboring a geneticin resistance gene 
(pSV40-neo) were added. The plasmid DNA’s were prepared by co- 
nrecinitation with 125 mM CaCl, in HBS-buffer (140 mM NaCl. 25 
mM HEPES, 0.75 mM Na,HPO,, pH 7.1). After 16 h the transfection 
medium was removed, and each monolayer was treated for 2.5 min with 
3 ml of 15% glycerol in PBS at room temperature. Cells were washed 
twice with HBS and cultured in fresh culture medium for 24 h. Stable 
transfectants were selected by culture in medium supplemented with 0.8 
mg/ml G418 (Gibco BRL, Eggenstein, Germany) for 12 days. 
2.4. Preparation of membrane fractions from transfected cells 
The transfected cells were homogenized and fractionated as previ- 
ously described [12] with a modification of a protocol previously em- 
ployed in 3T3-Ll cells [13]. 
2.5. Immunoblotting of the GLUT4 
Immunochemical detection and quantitation of the GLUT4 with 
antiserum against a dodekapeptide corresponding with the C-terminus 
of GLUT4 was performed as described previously [12]. 
2.6. Reconstitution of glucose transport activity from membrane 
fractions 
Glucose transport activity reconstituted into lecithin liposomes was 
assayed as described previously [ 141 with minor modifications [ 151. 
2.7. Photolabeling of glucose transporters with ‘2sI-IAPS-forskolin 
IAPS-forskolin (3-[‘25I]Iodo-4-azidophenetylamido-7-O-succinylde- 
acetyl-forskolin) was prepared as described-[16] and was stored in 
ethanol solution at -20°C. Photolabeling was nerformed bv a modifica- 
tion of a previously published procedure[l7]. Samples of plasma mem- 
branes (100 ~1) containing 30 ,ug of membrane protein were incubated 
with [‘251]IAPS-forskolin (2 ~1, 0.4 PCi, final concentration 50 nM) for 
30 min on ice. The samples were photolyzed by 6 flashes (setting on 
1,000 W. s) with the high pressure mercury lamp of the LIZZY photo- 
lysis flash (Raytest, Straubenhardt, Germany). The reaction was imme- 
diately quenched by addition of 10 ~110% /I-mercaptoethanol, and the 
samples were diluted with 1 ml of ice-cold Tris-buffer (20 mM). Mem- 
branes were separated by centrifugation in a refrigerated microfuge 
(13,500 rpm, 30 min), and the resulting pellets were separated by SDS- 
PAGE (10% gels). The gels were dried and autoradiographed for 2-7 
days. 
3. Results 
Since previous experiments had indicated that glucose 
transport activity in intact COS-7 cells does not increase 
proportionally with the expression of a transiently trans- 
fected GLUT4 or GLUT1 [12], we have chosen to assay 
the glucose transport activity of the mutants in an in 
vitro reconstitution assay. Membranes from transfected 
cells were solubilized, mixed with lecithin liposomes, and 
subjected to the freeze-thaw sonication procedure 
[14,15]. Control experiments were performed in which 
different amounts of DNA were employed in order to 
determine the optimum conditions of the transfection, 
and to assess the validity of the transport assay (data not 
shown). The expression of the wild-type GLUT4 in- 
creased gradually when amounts of DNA between 1 and 
7 ,ug per culture dish (57 cm’) were employed in the 
kDa 
IPM PM HD PM HD LD PM HD LD PM HD LD PM HD LD 
co GLUT4 Y29F Y143F Y432F 
IPM PM HD PM HD LD PM HD LD PM HD LD PM HD LD 
co GLUT4 Y292F Y293F Y309F 
Fig. 1. Immunochemical detection of the transiently expressed GLUT4 
mutants in membrane fractions from COS-7 cells. COS-7 cells were 
transfected with the GLUT4 mutant DNA subcloned into pCMV (25 
,ug/plate). After 48 h, cells were homogenized and fractionated by dilIer- 
ential fractionation as described. Samples of membrane proteins were 
separated by SDS-PAGE and immunoblotted. PM, plasma mem- 
branes; HD, high-density microsomes; LD, low-density microsomes. 
For comparison, samples of plasma membranes from insulin-treated 
adipocytes (IPM) were run in parallel. 
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glucose transporters. The results of three independent 
transfections and membrane preparations indicate that 
the mutants Y28F, Y292F, Y308F and Y432F induced 
an increase in glucose transport activity comparable to 
that of the wild type. In contrast, the glucose transport 
activity of Y143F was markedly reduced (30% of the 
wild-type GLUT4), whereas Y293F completely failed to 
increase the reconstituted transport activity (Fig. 2). 
Fig. 2. Reconstituted glucose transport activities of GLUT4 mutants 
transiently expressed in COS-7 cells. Samples (60 fig) of plasma mem- 
branes from COS-7 cells transfected with the indicated mutant DNA 
(25&plate) were solubilized, and glucose transport activity was recon- 
stituted and assayed as described in section 2. Glucose uptake rates in 
controls (transfection with bland vector) were routinely 15-25% of 
those in membranes containing wild-type GLUT4. After subtraction of 
the control rates, the data were corrected for different amounts of 
GLUT4 or GLUT4 mutants present in the membranes as assayed by 
immunoblotting in parallel samples. The data represent means f SE. 
of three independent transfection experiments, each assayed in quadru- 
plicate. 
transfection. In parallel, the glucose transport activity 
assayed with the reconstitution assay increased propor- 
tionally, and reached 6-lo-fold higher levels than the 
activity reconstituted from control cells. The amount of 
DNA giving rise to maximum GLUT4 expression 
(10 &2.5 x lo5 cells) was used routinely in all experi- 
ments and adjusted to the larger culture dishes employed 
subsequently (25 ,@plate with 6.25 x 10’ cells). 
When COS-7 cells were transfected with the wild type 
GLUT4 and the six mutants, all constructs were tran- 
siently expressed in comparable levels; there was no ap- 
parent difference between the mutants (Fig. 1). The 
subcellular distribution of the expressed mutants ap- 
peared essentially identical, with most of the protein de- 
tected in the plasma membrane fraction and approxi- 
mately 10% of that found in a low-density microsomal 
fraction. Fig. 2 illustrates a comparison of the reconsti- 
tuted glucose transport activities of six GLUT4 mutants. 
In these experiments, transfection with wild-type 
GLUT4 routinely produced a 45-fold increase of recon- 
stituted glucose transport activity over basal values. 
Equal amounts of membrane protein were used in the 
assays, and basal rates (membranes from transfection 
with bland pCMV vector) were subtracted from the re- 
sults. Thereafter, the data were corrected for slight differ- 
ences in the levels (immunoreactivity) of the expressed 
In order to confirm these results in an independent 
expression system, the wild-type GLUT4 and three of the 
mutants (Y143F, Y292F, Y293F) were transfected into 
LTK fibroblasts, and clones stably expressing the con- 
structs were isolated. The reconstituted glucose transport 
activity was 7-lo-fold higher in cells expressing the wild- 
type GLUT4 than in control clones transfected with 
bland vector. Values from control cells were subtracted, 
and the increments were corrected for differences in 
GLUT4 immunoreactivity assayed in separate samples. 
Table 1 summarizes the data obtained with the different 
mutants after this correction: the wild-type GLUT4 and 
the mutant Y292F produced an essentially identical in- 
crease of the reconstituted glucose transport activity. In 
contrast, the activity of Y143F was only 25% of that of 
the wild type, whereas Y293F appeared completely inac- 
tive. These data fully agree with the results obtained with 
the COS-7 cells. 
Several hydrophobic agents bind to glucose trans- 
porters and inhibit their activity. Among these, the pho- 
toreactive derivative IAPS-forskolin exhibits the highest 
affinity (ICsO of inhibition of glucose transport 3 x 10m8 
[16]). In order to test whether binding of the photolabel 
was affected in any of the mutant glucose transporters, 
membranes from transfected COS-7 cells were pho- 
tolyzed in the presence of tracer concentrations (0.4 ,uCi/ 
sample) of lz51-IAPS-forskolin. As is illustrated in Fig. 
3 (upper panel), covalent labeling of the GLUT4 resulted 
in a broad signal (45-50 kDa) reflecting the hetero- 
Table 1 
Reconstituted glucose transport activity of GLUT4 mutants stably 
expressed in LTK cells 
Reconstituted transport activity 
(nmol/lO min) 
wild type GLUT4 
Y143 
Y292F 
Y293F 
0.95 f 0.13 
0.22 f 0.04 
1.01 f 0.12 
not detectable 
Samples (60 pg) of plasma membranes from LTK cell clones stably 
expressing DNA were solubilized, and glucose transport activity was 
reconstituted and assayed as described in section 2. Glucose uptake 
rates in controls (transfection with bland vector) were routinely 1525% 
of those in membranes containing wild-type GLUT4. After subtraction 
of the control rates, the data were corrected for different amounts of 
GLUT4 or GLUT4 mutants present in the membranes as assayed by 
irnmunoblotting in parallel samples. The data represent means + S.E. 
of quadruplicate samples from a representative experiment. 
S. Wandel et al. IFEBS Letters 348 (1994) 114-118 
Cyto B - + - - + - + - + 
IPM Co GLUT4 Y28F Y143F 
Co Y292F Y293F Y308F Y432F 
A 
c 
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Fig. 3. Photolabeling of GLUTCmutants transiently expressed in COS- 
7 cells with ‘251-IAPS-forskolin. Samples (30 ,ug) of plasma membranes 
from COS-7 cells transfected with the indicated mutant DNA (25 fig/ 
plate) were photolyzed in the presence of 1251APS-forskolin as described 
in section 2. The membranes were isolated by centrifugation and sepa- 
rated by SDS-PAGE. Gels were dried and autoradiographed for 14 
days. Cyto B, presence of 25 PM cytochalasin B. For comparison, 
samples of plasma membranes from insulin-treated adipocytes (IPM) 
were run in parallel. Upper panel: autoradiograph of a representative 
experiment. Note that each sample contained an identical amount of 
total protein with a slightly different amount of transporter protein. 
Lower panel: the radioactivity incorporated into the 45-55 kDa bands 
were determined by cutting and scintillation counting, and was normal- 
ized for the different amounts of GLUT4 or GLUT4 mutants as as- 
sayed by immunoblotting in parallel samples. The data represent 
means f S.E. of 3 independent transfection experiments. 
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genous glycosylation of the transporter. The labeling was 
inhibited by glucose (not shown) or cytochalasin B. As 
can be judged from a comparison with a control (trans- 
fection with bland pCMV), labeling of the endogenous 
GLUT1 results in a much weaker signal which is distin- 
guishable from the transfected GLUT4 because of its 
lower electrophoretic mobility (apparent molecular 
weight 60 kDa). Thus, the results were quantitated by 
cutting and counting of the labeled band, and were nor- 
malized per GLUT4 immunoreactivity assayed in paral- 
lel samples (Fig. 3, lower panel). This normalization indi- 
cated that the labeling of all mutants was comparable 
with that of the wild-type GLUT4. In contrast to the 
results obtained in the reconstitution assay, photolabel- 
ing of Y 143F and Y293F was indistinguishable from that 
of the wild type. Furthermore, photolabeling of the mu- 
tants Y143F, Y292F and Y293F stably expressed in 
LTK cells was normal (data not shown). 
4. Discussion 
The present data indicate that out of the 6 conserved 
helical tyrosine residues only two, Y143 and Y293, are 
required for the transport activity of the GLUT4. Y293 
is conserved in all known mammalian hexose trans- 
porters, yeast glucose transporters, plant hexose-proton 
symporters [181, and some bacterial sugar-proton sym- 
porters. Y143 is conserved in all mammalian and some 
yeast, plant, and bacterial hexose transporters. Further- 
more, Y 143 is located within a highly conserved domain 
in helix 4 (VPMYV/IGEV/I) of the mammalian glucose 
transporters. It appears reasonable to conclude that the 
hydroxyl groups of these two tyrosines provide hydrogen 
bonds for the formation of the pore-forming complex of 
helices or represent contact sites for the substrate. The 
present data do not allow a distinction between these 
possibilities. However, the mutations have not produced 
a gross alteration of the quarternary structure of the 
protein, since binding of the label IAPS-forskolin to the 
mutant transporter was normal. Furthermore, when our 
manuscript was in preparation, a study was published 
showing that substitution of Y293 in the GLUT1 abol- 
ished the binding of the mannose-derived photolabel 
ATB-BMPA [19]. Thus, it appears safe to conclude that 
the loss of activity produced by mutation of Y293 reflects 
the specific alteration of an amino acid involved in trans- 
porter function, rather than a non-specific effect on the 
conformation of the protein. 
The current hypothesis on glucose transporter func- 
tion comprises a transport pathway formed by mem- 
brane spanning helices [5]. Specific permeation of glu- 
cose takes place by exofacial binding of the hexose, an 
induced conformational change of the pore-forming re- 
gion, and transfer of the hexose to an endofacial contact 
site. It has been suggested that a domain in helix 7 repre- 
118 
sents the exofacial recognition site of the hexose, since 
exchange of 4282 abolished the binding of the imper- 
meant, i.e. exofacial, photolabel ATP-BMPA [8]. Y293 
is located at the exofacial end of helix 7 and might be 
involved in the exofacial recognition of glucose, or be 
required for the conformational change of the trans- 
porter protein. Interestingly, a computerized assessment 
of the location of amino acids in helix 7 (HELWHEEL 
program) indicates that the residues 4282 and Y293 face 
the same side of the helix. 
The plant product forskolin is considered a specific 
ligand of mammalian glucose transporters (& approxi- 
mately 10m7 M in GLUT4, lO-‘j M in GLUTl, no specific 
binding detectable in GLUT2 [4]). Its binding to glucose 
transporters is inhibitable by glucose or cytochalasin B 
[20], suggesting that cytochalasin B, glucose and fors- 
kolin have common binding sites in the transporter pro- 
tein. The present data indicate that the structural re- 
quirements for glucose transport activity and forskolin 
binding, and probably also the respective contact sites, 
can partially be dissociated: whereas Y143 and Y293 
appear to be necessary for the function of the GLUT4, 
exchange of these residues failed to affect the binding of 
the forskolin-derived photolabel. Thus, the structural re- 
quirements determining glucose transport activity and 
IAPS-forskolin binding overlap only partially, e.g. for 
W388 [6,7], but not completely. This finding might indi- 
cate that forskolin, like cytochalasin B [5], binds exclu- 
sively to the internal contact site of glucose. 
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